Amalgamated Financial’s Utah Medical Products UTMD Stock Holding History

Amalgamated Financial’s Portfolio UTMD Stock Details UTMD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	$39K	Buy	+433	New	+$39.8K	﹤0.01%	2532

Other funds holding UTMD

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

RHJA

Rice Hall James & Associates San Diego, California $2.05B AUM 43.16% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Russell Investments Group London, United Kingdom $114B AUM 41.71% 1-Year Est. Return

RIM

Ranger Investment Management Dallas, Texas $1.38B AUM 24.55% 1-Year Est. Return

Amalgamated Financial's UTMD Position: Q1 2022 in Review

Amalgamated Financial opened a new position in Utah Medical Products (UTMD) in Q1 2022: 433 shares worth $39K. The stake represents ﹤0.01% of the portfolio and ranks #2532 among its holdings.

85 funds tracked by Wall St. Rank hold UTMD as of Q1 2022.

Amalgamated Financial held 433 shares of Utah Medical Products worth $39K as of Q1 2022.
Utah Medical Products was a new Amalgamated Financial position in Q1 2022.
Utah Medical Products made up ﹤0.01% of Amalgamated Financial's portfolio in Q1 2022, its #2532 holding.
85 funds tracked by Wall St. Rank held Utah Medical Products as of Q1 2022.

Based on Amalgamated Financial's 13F filing for Q1 2022, filed 16 May 2022.